ET GBS 329X525 Pg6 13022016

Total Page:16

File Type:pdf, Size:1020Kb

ET GBS 329X525 Pg6 13022016 AN ET EDGE INITIATIVE The evolving dynamics of the Healthcare industry The Healthcare roundtable at the Airtel and Economic Times Global Business Summit 2016 touched upon some crucial topics, most critically how to ensure healthcare reaches the furthest reaches of India's population t was Mahatma Gandhi who said that the ef- ficacy of a policy is best measured by seeing DR ANUPAM SIBAL, how it affects the most downtrodden sections Group Medical Director, I Apollo Hospitals Group of society. Although the government has taken "Clearly, for a country our size, we several steps towards eliminating healthcare need to augment capacity. There are related issues but there are many miles to be cov- some pretty simple solutions to this. ered before the job is considered done. It is in- The average intake of an Indian deed heartening to see that the sector has re- medical school is far below the global average. This despite us ceived a sizeable allocation in the last budget, having more people and more with an increase in size to 2.5% of the GDP. The patients in hospitals." current plan is a step ahead in the journey to- wards quality healthcare for all, and the belief that this is a trend that will continue with future budgets. BHAVDEEP SINGH, India's burgeoning populace is seen in many CEO, Fortis Healthcare circles as a positive, and while that is doubtless- "I find the problem with the way we ly true, it is also essential that we make the most define partnerships today is that we continue to sit in two different rooms of our human capital by ensuring our healthcare and have two different system is in optimal condition to take care of conversations. A good partnership is them all. With India's sprawling populace spread when we become less reactive and far and wide, this is no small challenge. more proactive." Compounding the issue is the fact that spending on health care in India was an estimated five percent of gross domestic product (GDP) in A VAIDHEESH, Managing Director, GlaxoSmithKline Pharmaceuticals 2013 and is expected to remain at "Somewhere down the line, there is a that level through 2016. misnomer of medicinal access being India's public health care system is not con- > From left to right: Satish Reddy (Chairman, Dr Reddy's), Bhavdeep Singh (CEO, Fortis Healthcare), A Vaidheesh (Managing Director, GlaxoSmithKline equal to reduced price. We need sistently spread, and thus last mile connectivity Pharmaceuticals), Moderator: Muralidharan Nair (Partner & National Leader, Healthcare, Ernst & Young), Dr Anupam Sibal (Group Medical Director, Apollo Hospitals established protocols and guidelines is always going to be a challenge. With under- Group) and Dr Sanjeev K Chaudhry (Chairman & Managing Director, SRL Diagnostics and a patient-care pathway. We need to put effort behind primary care so funded and overcrowded hospitals and clinics, that specialists are left to focus on and inadequate rural coverage, universal health- tion of financial costs for all sections of society. It only 30% of India's population. Unqualified prac- hoc manner. This becomes all the more neces- more complex cases." care remains a challenge in India. Considering is after doing so that we can turn our attention to titioners tend to the needs of Indians living in ru- sary because of the long payback periods for a that there has been a noticeable growth in age taking care of particularly vulnerable groups such ral and semi urban areas, and this is an issue that capital intensive sector such as healthcare. and lifestyle-related chronic diseases, this be- as children, women, disabled and the aged. can only be addressed by the dual pronged One means of bridging this gap between de- comes all the more alarming. India's health care However, this is easier said than done. The sta- emergence of more professionals and more hos- mand and supply is to create public-private SATISH REDDY, sector witnesses close to 50% spend on in-pa- tistics for India's health infrastructure are lagging pitals. partnerships, for it is only through a combina- Chairman, Dr Reddy's tient beds for lifestyle diseases, especially in urban behind that of other large countries that are ad- There is much hope to be had though since tion of government and corporate partnerships "It is important that community and semi-urban areas. mittedly far more developed. The U.S. has one the government earmarked the healthcare sector that we can create much-needed infrastruc- programs are designed to be A prime example of this is Diabetes, with 70 bed for every 350 patients while the ratio for as a major part of its 2014-2015 budget. In addi- ture. It is also necessary for organizations to ful- sustainable. You can't be waiting for the project to be funded by a million Indians affected by Diabetes and anoth- Japan is 1 for 85. India can only offer one bed for tion to approving a rise in the Foreign Direct ly embrace technology in order to deliver a bet- company, or to be delivered by a er 30 million in the prediabetes group, this is an every 1,050 patients, drawing a line under the Investment limit in the medical insurance busi- ter quality of service and improve the overall foundation and then taking over." issue that is just beginning to manifest itself. By need for massive investments in order to achieve ness to 49 percent, it also accorded four more quality of life. 2030, India is projected to have the largest num- the kind of last mile connectivity that enables ac- medical institutions with the status of All India The challenges are aplenty, but so are the ber of Diabetes patients in the world. This trend cess to healthcare for all. Institute of Medical Sciences (AIIMS) and broad- opportunities when it comes to Indian health- has resulted in the mushrooming of super spe- Concomitantly, there is also a need for quali- band connectivity in rural areas to enable the use care. By reimagining healthcare delivery mod- DR SANJEEV K CHAUDHRY, cialty hospitals to combat lifestyle diseases. fied medical professionals to staff the new health- of telemedicine for the remotest of the popula- els, patients are now getting closer than ever Chairman & Managing Director, This is just a glimpse of the challenge that lies care infrastructure that will doubtlessly crop up. tion. The budget also had provisions for the set- to much-needed healthcare. As the govern- SRL Diagnostics before India, for healthcare needs to cover not India's ratio of 0.7 doctors and 1.5 nurses per ting up of 15 model rural health research centers ment becomes more of a payer than provider, "For healthcare access to be successfully unlocked in this country for a large merely medical care but also preventive meas- 1,000 people is far lower than the WHO average to bridge the rural-urban divide. the neediest sections of society will find that number of people, I think the first step ures. Ironically, private out-of-pocket expenditure of 2.5 doctors and nurses per 1,000 people. This However, the absence of a central regulatory they are the beneficiaries of greater protection. is detection. "Am I well" is the question dominates the cost spectrum healthcare, yet pre- issue becomes all the more acute when you con- authority that monitors both government and pri- In time, there is a belief that the health of our that needs to be answered, and ventive care is put on the backburner. Thus, there sider the sheer scale of India's population, and vate-sector health care providers is a must along- nation's great population will be much more therefore detection, screening and diagnostics holds the key to a is a need for universal access, and access to an the fact that a majority of medical professionals side establishing health care facility standards, lest secure as a result of policy changes and sec- successful universal health program." adequate level of healthcare with a fair distribu- are to be found in urban areas, which comprises development of future facilities be done in an ad toral developments. Building up the Real Estate sector The road ahead for The potential is immense, but to be all it can, The transforming the Real Estate sector needs to be freed. Here are three key action areas for the industry. nature of Indian IT the Logistics industry he numbers tell a story of their own. Achuthan Nair (Senior Vice President & Chief There are many things that move the With an urban population equivalent Operating Officer, Wipro Infotech) talks about the Tto the total population of the United nation, but the Logistics industry does so State of America and United Kingdom, and evolving landscape of Information Technology in about 10 million people moving into cities the Indian context, as well as where it's heading above all. Shashi Kiran Shetty (Founder and annually, the Indian Real Estate sector is ex- hibiting the kind of robust growth that catch- ith its long legacy and forward cess affordability and acceptability to Chairman, Allcargo Logistics) speaks about es the eye. This, coupled with a housing Permission Requested looking strategy, Wipro technology for individuals and busi- the prospects of this bulwark sector shortage of 18.8 million, means it doesn't Call it red-tape, hurdles or whatever you WInfotech is among the leader in nesses alike, especially MSME. take a genius to understand the innate po- will, but permissions and approvals are a the managed IT Services industry in Access means the ability of citizens tential of the sector.
Recommended publications
  • Healthcare Sector in India Flanders Investment & Trade Market Survey
    HEALTHCARE SECTOR IN INDIA FLANDERS INVESTMENT & TRADE MARKET SURVEY Healthcare Sector in India Flanders Investment & Trade Economic Representation of Flanders c/o Embassy of Belgium 50 - N, Shantipath, Chanakyapuri New Delhi - 110 021 India [email protected] T: +91 11 42 42 81 00 F: +91 11 42 42 81 10 Studie Healthcare Sector in India | juni 2015 1 2 TABLE OF CONTENTS ICT in Healthcare Services in India ................................................................................................. 8 Introduction ......................................................................................................................................... 8 Healthcare Information & Communication Technology (HICT) ...................................................... 9 Patient Monitoring & Tracking ........................................................................................................ 9 Healthcare Information Technology (HIT) ..................................................................................... 10 National Health Policy ................................................................................................................... 10 Health Information Management Systems (HIMS) ....................................................................... 10 Grading of Indian States for the use of ICT in Hospitals ................................................................ 12 Telemedicine ....................................................................................................................................
    [Show full text]
  • FHL Annual Report 2020-21
    ANNUAL REPORT 2020-2021 COMPANY INFORMATION CONTENTS BOARD OF DIRECTORS CORPORATE OVERVIEW CLINICAL EXCELLENCE Chairman 02 Introduction 66 Dedicated to Serve Responsibly Ravi Rajagopal (Independent Director) 04 Vision and Mission AWARDS AND ACCOLADES 06 Values Vice-Chairman 74 Inspired By Recognitions Shirish Moreshwar Apte (Non-Executive Director) 08 Key Performance Highlights 2020-21 HUMAN RESOURCES Managing Director and CEO BOARD OF DIRECTORS 78 Inspiring Trust Through the People Power Dr. Ashutosh Raghuvanshi 10 Fortis Healthcare Limited 12 SRL Limited Non-Executive Directors STATUTORY REPORTS Dilip Kadambi MANAGEMENT COMMUNIQUE 84 Director’s Report Dr. Farid Bin Mohamed Sani 136 Report on Corporate Governance 14 From the Chairman’s Desk Heng Joo Joe Sim 164 Business Responsibility Report Joerg Ayrle 18 MD & CEO’s Message (FHL) 175 Management Discussion and Analysis Report Dr. Kelvin Loh Chi-Keon 22 CEO’s Message (SRL) Takeshi Saito FINANCIAL STATEMENTS COVID-19 AND OUR RESPONSE Independent Directors 26 A Clear and Compelling Purpose 191 Standalone Financials Indrajit Banerjee 283 Consolidated Financials Shailaja Chandra FORTIS HEALTHCARE LIMITED Suvalaxmi Chakraborty 32 Inspiring Trust Across the Nation Chief Financial Officer OUR TRANSFORMATION Vivek Kumar Goyal 38 The New Journey Company Secretary and Compliance Officer FINANCIAL HIGHLIGHTS Sumit Goel 40 Performance Snapshot Auditors CLINICAL FOCUS B S R & Co. LLP Chartered Accountants 44 New Clinical Offerings Fortis Healthcare Limited 46 Speciality Mix CIN: L85110PB1996PLC045933
    [Show full text]
  • Fortis Healthcare Limited
    FORTIS HEALTHCARE LIMITED Earnings Presentation – Q2FY21 November 12, 2020 Disclaimer This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction. This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements.
    [Show full text]
  • Fortis Healthcare Limited Investor Presentation – Q3 FY2013
    Fortis Healthcare Limited Earnings Presentation – FY20 and Q4 FY20 June 17, 2020 Disclaimer This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction. This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements.
    [Show full text]
  • Inner 25 India Pharma & Healthcare Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
    [Show full text]
  • “Re-Engineering Indian Healthcare”
    “Re‐engineering Indian Healthcare” Aug 31 ‐Sep 1, 2016 FICCI, New Delhi PROGRAM As on August 30, 2016 Day 1 – Wednesday, August 31, 2016 8:30 am Registration 10:00 am – 11:20 am Opening Session Session Moderator Ms Shobha Mishra Ghosh, Senior Director, FICCI Welcome Address Dr Nandakumar Jairam, Chair, FICCI Health Services Committee; Chairman, NABH & Chairman & Group Medical Director, Columbia Asia Hospitals India Presentation on 10th year of HEAL Ms Shobha Mishra Ghosh, Senior Director, FICCI Theme Address Mr Vishal Bali, Chair, FICCI HEAL 2016 Organizing Committee; Co‐Chair, FICCI Health Services Committee & Asia Head ‐ Healthcare, TPG Growth Keynote Address Mr Sunil Kant Munjal, Jt. Managing Director, Hero Motocorp Ltd. & Chairman, Hero Corporate Service Ltd. Release of Knowledge Paper: FICCI‐ EY paper on ‘Nursing Reforms: A paradigm shift for bright future’ Announcement of Poster Presentation Competition on the Theme “Re‐ engineering Indian Healthcare’ Keynote Address Mr C K Mishra, Secretary, Ministry of Health & Family Welfare, GoI Vote of Thanks Dr A Didar Singh, Secretary General, FICCI On Dais Mr Ashok Kakkar, Co‐Chair, FICCI Health Services Committee and Senior MD, Varian Medical Systems International India Pvt Ltd 11:20 am ‐ 11:45 am Tea Break 1 “Re‐engineering Indian Healthcare” Aug 31 ‐Sep 1, 2016 FICCI, New Delhi 11:45 am – 12:30 pm Keynote Session Moderator: Dr Nandakumar Jairam, Chair, FICCI Health Services Committee; Chairman, NABH & Chairman & Group Medical Director, Columbia Asia Hospitals India Presentation on the
    [Show full text]
  • CORPORATE PRESENTATION January 2021 DISCLAIMER
    CORPORATE PRESENTATION January 2021 DISCLAIMER The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person
    [Show full text]
  • Partial List Ex Conference 20
    Artemis Health Institute Bharat Serums & Vaccines Carrier CP Milk & Food Products Discovery FCDO GlaxoSmithkline Henkel India Shelter Finance Corporation Kadtech Infraprojects LSEG MIND NIIT Paytm Money PT Bank BTPN RTI Shyam Spectra Stryker ThoughtWorks ValueMined Technologies Y-Axis Solutions Arth Group Bharti Axa Life Insurance Cars24 CP Plus Dksh FE fundinfo Glenmark Pharmaceuticals Herbalife Nutition IndiaMART Kaivalya Educatiion Foundation LTI MindTickle Nineleaps technology solutions PayU PT. Media Indra Buana Ruby Seven Studios Shyam Spectra STT Global Data Centres Thryve Digital Valuex Technologies Yamaha Motor Arvind Fashions Bhel Caterpillar CP Wholesale DLF Fedex GlobalEdge Here Technologies Indigo Kalpataru Luminous Power Technologies Mindtree Nippon Koei PCCPL PTC Network Rustomjee Sidel Successive Technologies Tierra Agrotech Varroc Engineering Yanbal Asahi India Glass BIC CDK Global CPI DMD ADVOCATES Ferns n Petals GlobalLogic Herman Miller Indmoney Kama Ayurveda Luthra Group MiQ Digital NISA Global PCS Publicis Media S P Setia Siemens Sulzer Pumps Tifc Varuna Group Yanmar TAKE A LOOK AT LIST OF Ashirvad Pipes Bidgely Technologies CEAT Creditas Solutions DP World Ferrero GMR Hero Indofil industries Kanishk Hospital Luxury Personified Mizuho Bank Nissan Peak Infrastructure Management PUMA Group S&P Global Sigma AVIT Infra Services Summit Digitel Infrastructure TIL Vastu Housing Finance Corpora- Yara COMPANIES WHO WILL JOIN Asian paints Bigtree Entertainment Celio Cremica Dr Reddy's Ferring Pharmaceuticals Godrej & Boyce
    [Show full text]
  • Phd in Healthcare and Hospital Management Brochure
    ICRI Pune - Institute Of Clinical Research India Pune Charholi Budruk, Pune | Private PhD in Healthcare and Hospital Management Doctorate Degree | Full T ime | Duration - 3 years Medium English Highlights Candidates have the flexibility of choosing their guide /mentor which is provided by ICRI and the University The maximum duration of the course is 5 years Candidates, who have little knowledge of Healthcare, will undergo 6 months of academi After 6 months candidates work on their thesis in conjunction with their guide/mentor a c work which cover areas of the basics of Healthcare nd have the facility to meet them according to mutual convenience Eligibility & Cut-Off Qualification ICRI Entrance Exam Other eligibility criteria Masters in hospital administration/operations /management /public health policy or masters in a managerial subject with min 55 % Disclaimer: This is no t the o fficial bro chure o f this co urse. It is auto -g enerated based o n the info rmatio n available o n Shiksha as o n 15-Jan-2019. Admission Process Reg ister and Apply Interested candidates can apply online or offline with the required information. Entrance Test Eligible candidates need to appear for the Entrance Test conducted by the university. Personal Interview Shortlisted candidates will be called for personal interview based on marks obtained in the Entrance Exam. Final Selection Candidates are selected based on entrance exam marks and performance in personal interview. Fees General category T otal Fees INR 41,000 (Fees Components : Admission) Above fee
    [Show full text]
  • (Lux) Worldwide Fund
    Semi-Annual Report 30 September 2020 Wells Fargo (Lux) Worldwide Fund ▪ Alternative Risk Premia Fund ▪ China Equity Fund ▪ Emerging Markets Equity Fund ▪ Emerging Markets Equity Income Fund ▪ EUR Investment Grade Credit Fund ▪ EUR Short Duration Credit Fund ▪ Global Equity Fund ▪ Global Equity Absolute Return Fund ▪ Global Equity Enhanced Income Fund ▪ Global Factor Enhanced Equity Fund ▪ Global Investment Grade Credit Fund ▪ Global Long/Short Equity Fund ▪ Global Low Volatility Equity Fund ▪ Global Multi-Asset Income Fund ▪ Global Opportunity Bond Fund ▪ Global Small Cap Equity Fund ▪ Small Cap Innovation Fund ▪ U.S. All Cap Growth Fund ▪ U.S. High Yield Bond Fund ▪ U.S. Large Cap Growth Fund ▪ U.S. Select Equity Fund ▪ U.S. Short-Term High Yield Bond Fund ▪ U.S. Small Cap Value Fund ▪ USD Government Money Market Fund ▪ USD Investment Grade Credit Fund Alternative Risk Premia Fund, China Equity Fund, EUR Short Duration Credit Fund, Global Equity Enhanced Income Fund, Global Factor Enhanced Equity Fund, Global Investment Grade Credit Fund, Global Small Cap Equity Fund, Small Cap Innovation Fund and USD Government Money Market Fund have not been authorised by the Hong Kong Securities and Futures Commission and are not available for investment by Hong Kong retail investors. Wells Fargo (Lux) Worldwide Fund is incorporated with limited liability in the Grand Duchy of Luxembourg as a Société d’Investissement à Capital Variable under number RCS Luxembourg B 137.479. Registered office of Wells Fargo (Lux) Worldwide Fund: 80, route d’Esch, L-1470 Luxembourg, Grand Duchy of Luxembourg. Table of Contents Portfolio of investments Alternative Risk Premia Fund .......................................
    [Show full text]
  • 2021 Creative Agencies New Business
    2021 CREATIVE AGENCIES NEW BUSINESS India / Feb 2021 ESTIMATED ESTIMATED YTD RANK THIS RANK LAST OVERALL YTD No.of AGENCY RECENT WINS WIN REVENUE RECENT LOSSES MONTH MONTH REVENUE Wins (Crore) (Crore) Unilever Wall's Global, PoCo 1 13 DDB Mudra Group 21.1 21.1 9 Mobiles Project, Twin Health Marico, KFC Projects, Axis Bank 2 1 VMLY&R 20.9 Bel Cheese 20.9 27 Project 3 2 IPG Team Dynamic BMW 13.4 13.4 1 4 3 The Womb MPL, WheelsEMI 12.9 12.9 2 Emami Ltd, Lixil India, Dole Asia 5 Wondrlab 7.4 7.4 19 Holdings Project MullenLowe Group Waah Jobs, AkzoNobel Brands, 6 8 7.2 7.2 8 Lintas Group UPSTOX Awlencan Innovations India, 7 5 Havas Worldwide Dabur Tea, Visual Wizard 6.2 6.2 7 Acadamy IOCL (India Oil) 8 4 FCB Lamke, Elle 18 6.7 5.4 2 Project 9 7 Leo Burnett Udemy Project 3.5 Fortis Healthcare 3.5 7 Carrier Airconditioning and Refrigeration, Coromandel 10 15 Wunderman Thompson 3.2 3.2 7 Project, GlaxoSmithKline India Project Publicis + Publicis 11 6 Capital Foods 2.2 2.2 1 Ambiance Manipal-UNEXT Project, Aster DM 12 9 McCann WorldGroup 1.2 1.2 3 Healthcare Project, Y-Axis, Tata Mutual Fund Project, 13 12 Grey Group 0.7 0.7 3 Aditya Birla Group Project 14 10 BBDO Finance Client 0.4 0.4 2 CaratLane, Hotstar Project, 15 11 BBH 0.2 0.2 3 GoodWorker Project 16 14 Ogilvy Acko General Insurance Project 0.1 0.1 1 2021 (Jan-Feb): 103.5 105 2020 (Jan-Feb): 77.4 69 YoY Comparison: 33.7% 52.2% 1 2021 MEDIA AGENCIES NEW BUSINESS India / Feb 2021 ESTIMATED ESTIMATED YTD RANK THIS RANK LAST OVERALL YTD No.of AGENCY RECENT WINS WIN REVENUE RECENT LOSSES MONTH
    [Show full text]
  • Rethinking Cross-Border Talent Management: the Emerging Markets Perspective Tejpavan Gandhok
    Singapore Management University Institutional Knowledge at Singapore Management University Research Collection Lee Kong Chian School Of Lee Kong Chian School of Business Business 11-2014 Rethinking cross-border talent management: The emerging markets perspective Tejpavan Gandhok Richard SMITH Singapore Management University, [email protected] Follow this and additional works at: https://ink.library.smu.edu.sg/lkcsb_research Part of the Asian Studies Commons, Human Resources Management Commons, International Business Commons, and the Strategic Management Policy Commons Citation Gandhok, Tejpavan and SMITH, Richard. Rethinking cross-border talent management: The mee rging markets perspective. (2014). Asian Management Insights. 1, (2), 18-25. Research Collection Lee Kong Chian School Of Business. Available at: https://ink.library.smu.edu.sg/lkcsb_research/4359 This Magazine Article is brought to you for free and open access by the Lee Kong Chian School of Business at Institutional Knowledge at Singapore Management University. It has been accepted for inclusion in Research Collection Lee Kong Chian School Of Business by an authorized administrator of Institutional Knowledge at Singapore Management University. For more information, please email [email protected]. 18 INDUSTRY WATCH Rethinking Cross-Border Talent Management A closer look at the relatively little understood issue of how and why THE EMERGING MARKETS PERSPECTIVE emerging market MNCs manage their senior talent for international growth leads us to question the conventional wisdom on talent management practices. By Tejpavan Singh Gandhok and Richard R. Smith Markets are grappling with volatility and management approach is thus a must for the were publicly-listed, had recorded over 25 unpredictability, and becoming increasingly health, prosperity and long term viability of percent sales outside India with operations in reactive to economic conditions surrounding many organisations and their ambitious more than four countries, and had revenues them.
    [Show full text]